Exercise-induced myokines and their effect on prostate cancer
Top Cited Papers
- 22 June 2021
- journal article
- review article
- Published by Springer Nature in Nature Reviews Urology
- Vol. 18 (9), 519-542
- https://doi.org/10.1038/s41585-021-00476-y
Abstract
Exercise is recognized by clinicians in the field of clinical oncology for its potential role in reducing the risk of certain cancers and in reducing the risk of disease recurrence and progression; yet, the underlying mechanisms behind this reduction in risk are not fully understood. Studies applying post-exercise blood serum directly to various types of cancer cell lines provide insight that exercise might have a role in inhibiting cancer growth via altered soluble and cell-free blood contents. Myokines, which are cytokines produced by muscle and secreted into the bloodstream, might offer multiple benefits to cellular metabolism (such as a reduction in insulin resistance, improved glucose uptake and reduced adiposity), and blood myokine levels can be altered with exercise. Alterations in the levels of myokines such as IL-6, IL-15, IL-10, irisin, secreted protein acidic risk in cysteine (SPARC), myostatin, oncostatin M and decorin might exert a direct inhibitory effect on cancer growth via inhibiting proliferation, promoting apoptosis, inducing cell-cycle arrest and inhibiting the epithermal transition to mesenchymal cells. The association of insulin resistance, hyperinsulinaemia and hyperlipidaemia with obesity can create a tumour-favourable environment; exercise-induced myokines can manipulate this environment by regulating adipose tissue and adipocytes. Exercise-induced myokines also have a critical role in increasing cytotoxicity and the infiltration of immune cells into the tumour.Keywords
This publication has 244 references indexed in Scilit:
- Identification and Validation of Novel Contraction-Regulated Myokines Released from Primary Human Skeletal Muscle CellsPLOS ONE, 2013
- Bone matrix osteonectin limits prostate cancer cell growth and survivalMatrix Biology, 2012
- Marginating Dendritic Cells of the Tumor Microenvironment Cross-Present Tumor Antigens and Stably Engage Tumor-Specific T CellsCancer Cell, 2012
- A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesisNature, 2012
- Anti-cancer role of SPARC, an inhibitor of adipogenesisCancer Treatment Reviews, 2011
- The effects of a soluble activin type IIB receptor on obesity and insulin sensitivityInternational Journal of Obesity, 2009
- Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1The Journal of Experimental Medicine, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- SPARC Inhibits Adipogenesis by Its Enhancement of β-Catenin SignalingJournal of Biological Chemistry, 2009
- Mighty is a novel promyogenic factor in skeletal myogenesisExperimental Cell Research, 2008